High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors

(2014) I. Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

(2013) Anne-Geneviève Marcelin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil

(2013) Jaqueline de Souza Cavalcanti et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen

(2012) Jaqueline Souza Cavalcanti et al.   ANTIVIRAL RESEARCH

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

(2012) F. Saladini et al.   CLINICAL MICROBIOLOGY AND INFECTION

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

(2009) O. Delelis et al.   NUCLEIC ACIDS RESEARCH